Incyte announces new management

FRAMINGHAM (10/22/2003) - Incyte Corp. president and chief scientific officer Robert Stein has resigned from Incyte to become president of Roche Palo Alto LLC. Stein succeeds James N. Woody, who is leaving Roche after seven years in his current position. Incyte also announced that Richard Levy has joined the company as senior vice president of drug development, and GlaxoSmithKline's John A. Keller has taken the newly created position of executive vice president and chief business officer.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about GlaxoSmithKlineRoche

Show Comments